Drug reference
ramosetron
5-HT3 antagonist
5-HT3 antagonist
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
It is a potent 5-HT3 antagonist.
Indications
chemotherapy induced nausea and vomiting (CINV)postoperative nausea and vomiting (PONV)diarrhoea-predominant irritable bowel syndrome
Dosing
- Adult
- For CINV: 0.3 mg i.v. before chemotherapy, repeated once daily. For low emetogenic CINV: 0.1 mg oral once daily.
Related guidelines
Irritable bowel syndrome
ISG · Gastroenterology · 2023
Acute diarrhoea in children
IAP · Pediatrics · 2022
Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Acute coronary syndrome in chronic kidney disease
CSI · Cardiology · 2020
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Ask House about ramosetron
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: KD Tripathi 7e·Updated: 2026-05-10